Sodium selenite inhibits leukemia HL-60 cell proliferation and induces cell apoptosis by enhancing the phosphorylation of JNK1 and increasing the expression of p21 and p27

Wu,Sun; Bao,Yonghua; Ma,Dong; Zi,Youmei; Yang,Cui; Yang,Man; Xing,Mengtao; Yang,Wancai

doi:10.3892/ijmm.2014.1854

Sodium selenite inhibits leukemia HL-60 cell proliferation and induces cell apoptosis by enhancing the phosphorylation of JNK1 and increasing the expression of p21 and p27

Authors:
- Sun Wu
- Yonghua Bao
- Dong Ma
- Youmei Zi
- Cui Yang
- Man Yang
- Mengtao Xing
- Wancai Yang
View Affiliations

Affiliations: Department of Hematology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan, P.R. China, Department of Immunology, Xinxiang Medical University, Xinxiang, Henan, P.R. China, Department of Pathology, University of Illinois at Chicago, Chicago, IL, USA, Department of Pathology, Xinxiang Medical University, Xinxiang, Henan, P.R. China
Published online on: July 15, 2014 https://doi.org/10.3892/ijmm.2014.1854
Pages: 1175-1179

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Selenium is an essential trace element and has shown chemopreventive or therapeutic activities on human solid cancers; however, whether it has anticancer effects on leukemia has not yet been elucidated. The present study was designed to determine the role of selenium on HL-60 human promyelocytic leukemia cells. We found that 100 nM of sodium selenite (Se) had no significant effects on cell proliferation, apoptosis and the cell cycle; however, a higher concentration of 250 nM of Se significantly inhibited cell proliferation, promoted apoptosis and induced cell cycle arrest at the S phase after 48 h of treatment (P<0.05), thus demonstrating the anticancer activities of selenium in leukemia. However, the decrease in c-Jun NH2-terminal kinase 1 (JNK1) expression by targeting JNK1 using small interfering RNA attenuated the inhibitory effects of Se on cell proliferation and the induction of apoptosis. Mechanistic studies showed that the anticancer activities of Se were associated with the enhanced phosphorylation of JNK1 and the increased expression of the cell cycle regulators, p21 and p27, as well as the downregulation of cyclin D1. Our data provide further evidence that the appropriate concentration of selenium has therapeutic potential in leukemia.

View Figures

View References

1	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
2	Uğuz AC, Naziroğlu M, Espino J, Bejarano I, Gonzalez D, Rodriguez AB and Pariente JA: Selenium modulates oxidative stress-induced cell apoptosis in human myeloid HL-60 cells through regulation of calcium release and caspase-3 and -9 activities. J Membr Biol. 232:15–23. 2009.
3	Ip C: Lessons from basic research in selenium and cancer prevention. J Nutr. 128:1845–1854. 1998.PubMed/NCBI
4	Wang L, Bonorden MJ, Li GX, Lee HJ, Hu H, Zhang Y, Liao JD, Cleary MP and Lü J: Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev Res (Phila). 2:484–495. 2009. View Article : Google Scholar
5	Facompre N and El-Bayoumy K: Potential stages for prostate cancer prevention with selenium: implications for cancer survivors. Cancer Res. 69:2699–2703. 2009. View Article : Google Scholar : PubMed/NCBI
6	Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, et al: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial Nutritional Prevention of Cancer Study Group. JAMA. 276:1957–1963. 1996. View Article : Google Scholar
7	Greenwald P, Anderson D, Nelson SA and Taylor PR: Clinical trials of vitamin and mineral supplements for cancer prevention. Am J Clin Nutr. 85:314S–317S. 2007.PubMed/NCBI
8	Hawk ET and Levin B: Colorectal cancer prevention. J Clin Oncol. 23:378–391. 2005. View Article : Google Scholar
9	Peters U and Takata Y: Selenium and the prevention of prostate and colorectal cancer. Mol Nutr Food Res. 52:1261–1272. 2008. View Article : Google Scholar : PubMed/NCBI
10	Fang W, Han A, Bi X, Xiong B and Yang W: Tumor inhibition by sodium selenite is associated with activation of c-Jun NH2-terminal kinase 1 and suppression of beta-catenin signaling. Int J Cancer. 127:32–42. 2010. View Article : Google Scholar : PubMed/NCBI
11	Song Z, Tong C, Liang J, Dockendorff A, Huang C, Augenlicht LH and Yang W: JNK1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo. Eur J Pharmacol. 560:95–100. 2007. View Article : Google Scholar : PubMed/NCBI
12	Tong C, Yin Z, Song Z, Dockendorff A, Huang C, Mariadason J, Flavell RA, Davis RJ, Augenlicht LH and Yang W: c-Jun NH2-terminal kinase 1 plays a critical role in intestinal homeostasis and tumor suppression. Am J Pathol. 171:297–303. 2007. View Article : Google Scholar : PubMed/NCBI
13	Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell. 103:239–252. 2000. View Article : Google Scholar : PubMed/NCBI
14	Johnson GL and Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 298:1911–1912. 2002. View Article : Google Scholar : PubMed/NCBI
15	Hu D, Fang W, Han A, Gallagher L, Davis RJ, Xiong B and Yang W: c-Jun N-terminal kinase 1 interacts with and negatively regulates Wnt/beta-catenin signaling through GSK3beta pathway. Carcinogenesis. 29:2317–2324. 2008. View Article : Google Scholar : PubMed/NCBI
16	Yang WC, Mathew J, Velcich A, Edelmann W, Kucherlapati R, Lipkin M, Yang K and Augenlicht LH: Targeted inactivation of the p21(WAF1/cip1) gene enhances Apc-initiated tumor formation and the tumor-promoting activity of a Western-style high-risk diet by altering cell maturation in the intestinal mucosal. Cancer Res. 61:565–569. 2001.
17	van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis AP, et al: The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell. 111:241–250. 2002.PubMed/NCBI
18	Tetsu O and McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 398:422–426. 1999. View Article : Google Scholar : PubMed/NCBI
19	Lü J and Jiang C: Selenium and cancer chemoprevention: hypotheses integrating the actions of selenoproteins and selenium metabolites in epithelial and non-epithelial target cells. Antioxid Redox Signal. 7:1715–1727. 2005.
20	Diwadkar-Navsariwala V and Diamond AM: The link between selenium and chemoprevention: a case for selenoproteins. J Nutr. 134:2899–2902. 2004.PubMed/NCBI
21	Narayanan BA, Narayanan NK, Desai D, Pittman B and Reddy BS: Effects of a combination of docosahexaenoic acid and 1,4-phenylene bis(methylene) selenocyanate on cyclooxygenase 2, inducible nitric oxide synthase and beta-catenin pathways in colon cancer cells. Carcinogenesis. 25:2443–2449. 2004. View Article : Google Scholar
22	Rao CV, Cooma I, Rodriguez JG, Simi B, El-Bayoumy K and Reddy BS: Chemoprevention of familial adenomatous polyposis development in the APC(min) mouse model by 1,4-phenylene bis(methylene)selenocyanate. Carcinogenesis. 21:617–621. 2000. View Article : Google Scholar : PubMed/NCBI
23	Hu H, Jiang C, Ip C, Rustum YM and Lü J: Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells. Clin Cancer Res. 11:2379–2388. 2005. View Article : Google Scholar : PubMed/NCBI
24	Jiang C, Wang Z, Ganther H and Lu J: Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther. 1:1059–1066. 2002.PubMed/NCBI
25	Bi X, Pohl N, Dong H and Yang W: Selenium and sulindac are synergistic to inhibit intestinal tumorigenesis in Apc/p21 mice. J Hematol Oncol. 6:82013. View Article : Google Scholar : PubMed/NCBI
26	Hu D, Bi X, Fang W, Han A and Yang W: GSK3beta is involved in JNK2-mediated beta-catenin inhibition. PLoS One. 4:e66402009. View Article : Google Scholar : PubMed/NCBI
27	Bode AM and Dong Z: The functional contrariety of JNK. Mol Carcinog. 46:591–598. 2007. View Article : Google Scholar : PubMed/NCBI
28	Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, et al: Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 301:39–51. 2009. View Article : Google Scholar : PubMed/NCBI
29	Fang W, Goldberg ML, Pohl NM, Bi X, Tong C, Xiong B, Koh TJ, Diamond AM and Yang W: Functional and physical interaction between the selenium-binding protein 1 (SBP1) and the glutathione peroxidase 1 selenoprotein. Carcinogenesis. 31:1360–1366. 2010. View Article : Google Scholar : PubMed/NCBI
30	Chu IM, Hengst L and Slingerland JM: The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 8:253–267. 2008. View Article : Google Scholar : PubMed/NCBI